|
 |
Dihydroergotamine MesylateThis page contains recent news articles, when available, and an overview of Dihydroergotamine Mesylate but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Dihydroergotamine Mesylate (when available) Ergotamine is a vasoconstrictor and alpha adrenoreceptor antagonist. The pharmacological properties of ergotamine are extremely complex; some of its actions are unrelated to each other, and even mutually antagonistic. The drug has partial agonist and/or antagonist activity against tryptaminergic, dopaminergic and alpha adrenergic receptors depending upon their site, and it is a highly active uterine stimulant. It causes constriction of peripheral and cranial blood vessels and produces depression of central vasomotor centers. The pain of a migraine attack is believed to be due to greatly increased amplitude of pulsations in the cranial arteries, especially the meningeal branches of the external carotid artery. Ergotamine reduces extracranial blood flow, causes a decline in the amplitude of pulsation in the cranial arteries, and decreases hyperperfusion of the territory of the basilar artery. It does not reduce cerebral hemispheric blood flow. For use as therapy to abort or prevent vascular headache, e.g., migraine, migraine variants, or so called "histaminic cephalalgia". Mechanism Of Action: Ergotamine acts on migraine by one of two proposed mechanisms: 1) activation of 5-HT1D receptors located on intracranial blood vessels, including those on arterio-venous anastomoses, leads to vasoconstriction, which correlates with the relief of migraine headache, and 2) activation of 5-HT1D receptors on sensory nerve endings of the trigeminal system results in the inhibition of pro-inflammatory neuropeptide release. News Articles on Ergotamine Press Release: MAP Pharmaceuticals to Present MAP0004 Phase 2 … - Jun 5, 2007 Dihydroergotamine Mesylate, Injection Patient Medication Advisory This medicine is ... The Mosby Medical Encyclopedia 10-01-1996 dihydroergotamine mesylate, ... Pay-Per-View - PR Newswire - HighBeam Research MAP Pharmaceuticals to Present MAP0004 Phase 2 Clinical Data at the … - Jun 5, 2007 Comparative Clinical Pharmacokinetics of Parent Drug and Metabolites Following Inhaled Dosing with Dihydroergotamine Mesylate via a Novel System (Tempo(TM) ... Genetic Engineering News - Genetic Engineering News (press release) MAP Pharmaceuticals To Present MAP0004 Phase 2 Clinical Data At The … - Jun 6, 2007 Clinical Safety of Inhaled Dihydroergotamine Mesylate via a Novel System (Tempo(TM) Inhaler); Poster ID F07; June 8, 12:30 to 1:30pm CDT. ... Medical News Today - Medical News Today (press release) Ergotamines for cluster headaches - Apr 11, 2008 Dihydroergotamine mesylate, which is generally given as a shot (DHE), is also available as a nasal spray (Migranal). DHE can also be given through a vein ... WebMD New Jersey Administrative Code - 10:58A-4.3 HCPCS procedure codes … - Aug 16, 2005 1 mg 0.50 J1100 Injection, dexamethasone sodium 0.15 phosphate, 1 mg J1110 Dihydroergotamine Mesylate, 1 mg 15.36 J1120 Injection, acetazolamide sodium, ... Pay-Per-View - New Jersey Administrative Code - Loislaw Valeant Pharmaceuticals Introduces Redesigned Migranal Delivery … - Jun 27, 2005 Valeant Pharmaceuticals International (NYSE:VRX) unveiled its redesigned Migranal(R) (dihydroergotamine mesylate, USP) nasal sprayer, and presented ... RedOrbit MAP Pharmaceuticals Initiates Phase 2 Clinical Trial in Patients With... - Sep 5, 2006 MAP0004 is a novel inhaled drug formulation of dihydroergotamine mesylate (DHE) administered with MAP's patented Tempo(TM) Inhaler. ... Free with registration - PR Newswire - AccessMyLibrary.com Medications for migraine prophylaxis. - Jan 1, 2006 Evidence supports the use of timed-release dihydroergotamine mesylate, but patients should be monitored closely for adverse effects. ... Free with registration - American Family Physician - AccessMyLibrary.com MAP Pharmaceuticals Appoints New Program Directors. - Jul 19, 2006 ...to one of MAP's lead products, a novel inhaled drug formulation of dihydroergotamine mesylate (DHE) administered with MAP's patented Tempo Inhaler. ... Free with registration - PR Newswire - AccessMyLibrary.com Press Release: MAP Pharmaceuticals Reports Positive Pharmacological … - Jun 28, 2008 PR Newswire; June 24, 1993 ; 700+ words ... ... acute migraine following administration of DHE-45(R) (dihydroergotamine mesylate ... Pharmaceuticals Corp. ... Pay-Per-View - PR Newswire - HighBeam Research MAP Pharmaceuticals Reports Positive Phase 2 Results For Its Inhaled ... - Mar 2, 2007 By providing rapid onset with a novel formulation of a proven compound (dihydroergotamine mesylate), MAP Pharmaceuticals seeks to meet the treatment needs ... Medical News Today - Medical News Today (press release) Clinical trials update: September 2006.(Report) - Oct 16, 2006 Jazz Xyrem Sodium oxybate oral Pharmaceuticals (FDA-approved) solution Inc. * MAP MAP0004 Formulation of Pharmaceuticals dihydroergotamine mesylate Inc. ... Free with registration - Bioworld Financial Watch - AccessMyLibrary.com headache :: Migraine -- Britannica Online Encyclopedia - Jun 19, 2008 Migraine attacks of greater severity can sometimes be treated at the start with ergotamine, sumatriptan, dihydroergotamine mesylate (DHE-45), or caffeine; ... Subscription - Encyclopedia Britannica North Carolina Business Opinions - IN RE POZEN S'HOLDERS LITIG., … - Nov 10, 2005 MT 300, a "pre-filled syringe containing dihydroergotamine mesylate, or DHE," was designed "to provide long-lasting pain relief for patients via a ... Pay-Per-View - North Carolina Business Opinions - Loislaw Intranasal NSAID a first for pain relief - Jun 7, 2007 Already on the market is Stadol (butorphanol tartrate) analgesic nasal spray and Migranal (dihydroergotamine mesylate) nasal spray for migraines. ... In-PharmaTechnologist.com Overuse of headache drugs can be overcome.(Neurology) - Mar 1, 2007 Inpatients can be switched to intravenous DHE (dihydroergotamine mesylate) and outpatients can be given Migranal NS. A steroid taper is another option, ... Free with registration - Internal Medicine News - AccessMyLibrary.com Press Release: MAP Pharmaceuticals Initiates Phase 2 Clinical Trial... - Sep 5, 2006 MAP0004 is a novel inhaled drug formulation of dihydroergotamine mesylate (DHE) administered with MAP's patented Tempo(TM) Inhaler. ... Pay-Per-View - PR Newswire - HighBeam Research Players Still Trying To Widen Market For Migraine Therapy - Aug 20, 2007 Two earlier compounds - MT 300, a new formulation of dihydroergotamine mesylate, and MT 100, a naproxen/metoclopramide combo - got not-approvable letters ... BioWorld Online - BioWorld Online Clinical trials update: September 2006.(Report) - Oct 16, 2006 Pharmaceuticals dihydroergotamine mesylate Inc. * delivered with MAP's inhaler Medivation Dimebon Neuroprotectant agent Inc. (AMEX:MDV) that's been on the ... Pay-Per-View - Bioworld Financial Watch - Factiva, from Dow Jones MAP Pharmaceuticals Reports Positive Phase 2 Results for its Inhaled ... - Mar 1, 2007 By providing rapid onset with a novel formulation of a proven compound (dihydroergotamine mesylate), MAP Pharmaceuticals seeks to meet the treatment needs ... Free with registration - PR Newswire - AccessMyLibrary.com Valeant's 2nd-qtr 2007 income stays constant. - Aug 13, 2007 ...a topical treatment for actinic keratoses, the cannabinoid anti-emetic Cesamet (nabilone) and the migraine drug Migranal (dihydroergotamine mesylate). ... $9.94 - Pharma Marketletter - Alacra Store Woman With Short-Lasting, Strictly Unilateral Headaches. - Oct 1, 2007 ...eletriptan, and naratriptan); and most recently, dihydroergotamine mesylate (DHE) nasal spray. She has been hospitalized 3 times in the past 2 years; ... $4.95 - Consultant - ECNext Compass Healthcare Communications.(LAUNCHES) - Sep 1, 2007 Compass Healthcare Communications launched a new Web site for Migranal (dihydroergotamine mesylate), a nasal spray migraine medication. $4.95 - Pharmaceutical Executive - ECNext Valeant Pharmaceuticals to Partner with ASCEND Therapeutics to … - Oct 1, 2007 ...specialty sales force to promote Valeant's Migranal([R])(dihydroergotamine mesylate, USP) Nasal Spray to more than 5500 OB/GYNs in the United States. ... $4.95 - Business Wire - ECNext Brand Names/Synonyms: Dihydroergotamine Mesylate is also known by the following brand names and/or synonymsD.H.E. 45; Dihydroergotamine Mesylate; Ergomar; Ergostat; Ergotamin; Ergotamine; Ergoton-a [As Succinate]; Medihaler Ergotamine; Migranal; Wigrettes Drug Category: Dihydroergotamine Mesylate is categorized under the following by the FDA: Adrenergic alpha-Agonists; Analgesics, Non-Narcotic; Vasoconstrictor Agents; Sympatholytics; ATC:N02CA01; ATC:N02CA02 Dosage Forms: TABLET Absorption: Not Available Interactions: [an error occurred while processing this directive] Chemical IUPAC Name: Not Available |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |